000144814 001__ 144814
000144814 005__ 20240229123020.0
000144814 0247_ $$2doi$$a10.1093/nutrit/nuz039
000144814 0247_ $$2pmid$$apmid:31504850
000144814 0247_ $$2ISSN$$a0029-6643
000144814 0247_ $$2ISSN$$a1753-4887
000144814 0247_ $$2altmetric$$aaltmetric:65577658
000144814 037__ $$aDKFZ-2019-02239
000144814 041__ $$aeng
000144814 082__ $$a610
000144814 1001_ $$aJavelle, Florian$$b0
000144814 245__ $$aEffects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis.
000144814 260__ $$aLawrence, Kan.$$bInternat. Life Sciences Inst.$$c2020
000144814 3367_ $$2DRIVER$$aarticle
000144814 3367_ $$2DataCite$$aOutput Types/Journal article
000144814 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601379704_14558
000144814 3367_ $$2BibTeX$$aARTICLE
000144814 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144814 3367_ $$00$$2EndNote$$aJournal Article
000144814 500__ $$a2020 Jan 1;78(1):77-88#LA:C110#
000144814 520__ $$aSerotonergic dysfunction, including reduced central serotonin levels, is associated with different psychiatric syndromes, including depression. As a serotonin precursor, 5-hydroxytryptophan has long been used as a nonpharmacological treatment for depression.A systematic review and meta-analysis was conducted to determine the antidepressant effects of 5-hydroxytryptophan in depressed patients.MEDLINE (via PubMed) and Google Scholar were searched from inception to May 2018.Thirteen investigations were included in the systematic review (using PRISMA guidelines), and 7 in the full meta-analysis (pre-registered on PROSPERO: CRD42018104415).Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69). Methodological variability (in treatment duration, type of depression studied, experimental design, 5-hydroxytryptophan dosage) contributes to heterogeneity in the results (I2 = 76%, τ2 = 0.379). In addition, the OHAT (Office of Health Assessment and Translation risk of bias rating) tool suggested that, on the whole, current studies are relatively weak (few include placebo groups).Further trials should overcome these limitations by using placebo-controlled studies that include patients with well-defined depression diagnoses, along with strong characterization of psychological and physiological patient characteristics.
000144814 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144814 588__ $$aDataset connected to CrossRef, PubMed,
000144814 7001_ $$aLampit, Amit$$b1
000144814 7001_ $$aBloch, Wilhelm$$b2
000144814 7001_ $$aHäussermann, Peter$$b3
000144814 7001_ $$aJohnson, Sheri L$$b4
000144814 7001_ $$0P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aZimmer, Philipp$$b5$$eLast author$$udkfz
000144814 773__ $$0PERI:(DE-600)2066844-2$$a10.1093/nutrit/nuz039$$gp. nuz039$$n1$$p77-88$$tNutrition reviews$$v78$$x1753-4887$$y2020
000144814 909CO $$ooai:inrepo02.dkfz.de:144814$$pVDB
000144814 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144814 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144814 9141_ $$y2020
000144814 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144814 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144814 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144814 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144814 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUTR REV : 2017
000144814 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144814 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144814 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144814 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144814 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144814 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144814 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144814 915__ $$0StatID:(DE-HGF)1060$$2StatID$$aDBCoverage$$bCurrent Contents - Agriculture, Biology and Environmental Sciences
000144814 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144814 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNUTR REV : 2017
000144814 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000144814 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000144814 980__ $$ajournal
000144814 980__ $$aVDB
000144814 980__ $$aI:(DE-He78)C110-20160331
000144814 980__ $$aUNRESTRICTED